539 related articles for article (PubMed ID: 26864352)
21. Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.
Pilon D; Tandon N; Lafeuille MH; Kamstra R; Emond B; Lefebvre P; Joshi K
Clin Ther; 2017 Oct; 39(10):1972-1985.e2. PubMed ID: 28919292
[TBL] [Abstract][Full Text] [Related]
22. A comparison of recurrence rates after discontinuation of second-generation antipsychotic long-acting injectable versus corresponding oral antipsychotic in the maintenance treatment of bipolar disorder: A systematic review.
Kishi T; Citrome L; Sakuma K; Iwata N
Psychiatry Res; 2024 Mar; 333():115761. PubMed ID: 38301289
[TBL] [Abstract][Full Text] [Related]
23. Treatment discontinuation of long-acting injectables or oral atypical antipsychotics among Medicaid recipients with schizophrenia.
Song X; El Khoury AC; Brouillette M; Smith D; Joshi K
J Med Econ; 2019 Nov; 22(11):1105-1112. PubMed ID: 31062998
[No Abstract] [Full Text] [Related]
24. Hospitalization rates in patients switched from oral anti-psychotics to aripiprazole once-monthly: final efficacy analysis.
Kane JM; Zhao C; Johnson BR; Baker RA; Eramo A; McQuade RD; Duca AR; Sanchez R; Peters-Strickland T
J Med Econ; 2015 Feb; 18(2):145-54. PubMed ID: 25347448
[TBL] [Abstract][Full Text] [Related]
25. Antagonist and partial agonist at the dopamine D2 receptors in drug-naïve and non-drug-naïve schizophrenia: a randomized, controlled trial.
Takekita Y; Fabbri C; Kato M; Nonen S; Sakai S; Sunada N; Koshikawa Y; Wakeno M; Okugawa G; Kinoshita T; Serretti A
Eur Arch Psychiatry Clin Neurosci; 2015 Oct; 265(7):579-88. PubMed ID: 26016467
[TBL] [Abstract][Full Text] [Related]
26. Medication Adherence and Discontinuation of Aripiprazole Once-Monthly 400 mg (AOM 400) Versus Oral Antipsychotics in Patients with Schizophrenia or Bipolar I Disorder: A Real-World Study Using US Claims Data.
Yan T; Greene M; Chang E; Hartry A; Touya M; Broder MS
Adv Ther; 2018 Oct; 35(10):1612-1625. PubMed ID: 30206822
[TBL] [Abstract][Full Text] [Related]
27. Single- and multiple-dose pharmacokinetic, safety, and tolerability profiles of olanzapine long-acting injection: an open-label, multicenter, nonrandomized study in patients with schizophrenia.
Mitchell M; Kothare P; Bergstrom R; Zhao F; Jen KY; Walker D; Johnson J; McDonnell D
Clin Ther; 2013 Dec; 35(12):1890-908. PubMed ID: 24184052
[TBL] [Abstract][Full Text] [Related]
28. A safety evaluation of aripiprazole in the treatment of schizophrenia.
Preda A; Shapiro BB
Expert Opin Drug Saf; 2020 Dec; 19(12):1529-1538. PubMed ID: 33064050
[TBL] [Abstract][Full Text] [Related]
29. [Pharmacokinetics and safety of aripiprazole long-acting injection, following multiple deltoid administrations in schizophrenia patients in Japan].
Ishigooka J; Noda T; Nishiyama K; Tamaru N; Shima T; Yamasaki Y; Tadori Y
Nihon Shinkei Seishin Yakurigaku Zasshi; 2016 Jun; 36(3):63-8. PubMed ID: 27506082
[TBL] [Abstract][Full Text] [Related]
30. Efficacy, tolerability, and safety of aripiprazole once-monthly versus other long-acting injectable antipsychotic therapies in the maintenance treatment of schizophrenia: a mixed treatment comparison of double-blind randomized clinical trials.
Majer IM; Gaughran F; Sapin C; Beillat M; Treur M
J Mark Access Health Policy; 2015; 3():. PubMed ID: 27123183
[TBL] [Abstract][Full Text] [Related]
31. A review of aripiprazole long-acting injection.
Chue P; Chue J
Curr Med Res Opin; 2016; 32(3):441-52. PubMed ID: 26713457
[TBL] [Abstract][Full Text] [Related]
32. Comparison between long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophrenia: systematic review and indirect treatment comparison.
Pae CU; Wang SM; Han C; Bahk WM; Lee SJ; Patkar AA; Masand PS; Serretti A; Emsley R
Int Clin Psychopharmacol; 2017 Sep; 32(5):235-248. PubMed ID: 28430670
[TBL] [Abstract][Full Text] [Related]
33. Long-Acting Injectable (LAI) Aripiprazole Formulations in the Treatment of Schizophrenia and Bipolar Disorder: a Systematic Review.
Rapinesi C; Kotzalidis GD; Mazzarini L; Brugnoli R; Ferracuti S; De Filippis S; Cuomo I; Giordano G; Del Casale A; Angeletti G; Sani G; Girardi P
Clin Drug Investig; 2019 Aug; 39(8):713-735. PubMed ID: 31152368
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of aripiprazole once-monthly compared with paliperidone palmitate once-monthly injectable for the treatment of schizophrenia in the United States.
Citrome L; Kamat SA; Sapin C; Baker RA; Eramo A; Ortendahl J; Gutierrez B; Hansen K; Bentley TG
J Med Econ; 2014 Aug; 17(8):567-76. PubMed ID: 24758296
[TBL] [Abstract][Full Text] [Related]
35. Safety and tolerability of once monthly aripiprazole treatment initiation in adults with schizophrenia stabilized on selected atypical oral antipsychotics other than aripiprazole.
Potkin SG; Raoufinia A; Mallikaarjun S; Bricmont P; Peters-Strickland T; Kasper W; Baker RA; Eramo A; Sanchez R; McQuade R
Curr Med Res Opin; 2013 Oct; 29(10):1241-51. PubMed ID: 23822566
[TBL] [Abstract][Full Text] [Related]
36. Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study.
Kane JM; Peters-Strickland T; Baker RA; Hertel P; Eramo A; Jin N; Perry PP; Gara M; McQuade RD; Carson WH; Sanchez R
J Clin Psychiatry; 2014 Nov; 75(11):1254-60. PubMed ID: 25188501
[TBL] [Abstract][Full Text] [Related]
37. Evaluating the efficacy and safety of the currently available once-every-two months long-acting injectable formulations of aripiprazole for the treatment of schizophrenia or as a maintenance monotherapy for bipolar I disorder in adults.
Samalin L; Boudieu L; Llorca PM
Expert Rev Neurother; 2024 Mar; 24(3):291-298. PubMed ID: 38299536
[TBL] [Abstract][Full Text] [Related]
38. Symptoms and functioning with aripiprazole once-monthly injection as maintenance treatment for bipolar I disorder.
Calabrese JR; Sanchez R; Jin N; Amatniek J; Cox K; Johnson B; Perry P; Hertel P; Such P; McQuade RD; Nyilas M; Carson WH
J Affect Disord; 2018 Feb; 227():649-656. PubMed ID: 29174738
[TBL] [Abstract][Full Text] [Related]
39. Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia.
Naber D; Hansen K; Forray C; Baker RA; Sapin C; Beillat M; Peters-Strickland T; Nylander AG; Hertel P; Andersen HS; Eramo A; Loze JY; Potkin SG
Schizophr Res; 2015 Oct; 168(1-2):498-504. PubMed ID: 26232241
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of aripiprazole once-monthly in Asian patients with schizophrenia: a multicenter, randomized, double-blind, non-inferiority study versus oral aripiprazole.
Ishigooka J; Nakamura J; Fujii Y; Iwata N; Kishimoto T; Iyo M; Uchimura N; Nishimura R; Shimizu N;
Schizophr Res; 2015 Feb; 161(2-3):421-8. PubMed ID: 25556976
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
